戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mation, and another 3 of these 20 received a fibrinolytic agent.
2 nctive antithrombotic therapy, against other fibrinolytic agents, a placebo, or no treatment.
3 y randomised controlled trials that compared fibrinolytic agents as a reperfusion therapy in adult pa
4 r (VWF) concentrates, desmopressin, and anti-fibrinolytic agents as main tools to control bleeding.
5                          Patients received a fibrinolytic agent, aspirin, and when appropriate, hepar
6 re we show that activation of plasmin, a key fibrinolytic agent, by annexin A2 (ANXA2) distinctly imp
7                                            A fibrinolytic agent consisting of a tissue-type plasminog
8 eads to faster artery-opening treatment with fibrinolytic agents, either in the pre-hospital setting
9 hrombolysis and the potential novel use as a fibrinolytic agent for thromboprophylaxis without bleedi
10                               Treatment with fibrinolytic agents has shown promise but remains of unp
11                                              Fibrinolytic agents have also been used in other clinica
12 of streptokinase in 1933, several additional fibrinolytic agents have been developed.
13 e catalytic activation of plasmin, the major fibrinolytic agent in mammals.
14                       It is widely used as a fibrinolytic agent in thrombolytic therapy and it is als
15 b/IIIa receptor inhibitors with reduced-dose fibrinolytic agents in acute MI, with the goal of overco
16 ns, evolving roles, and future directions of fibrinolytic agents in thromboembolic diseases.
17      Finally, a new class of directly acting fibrinolytic agents is available.
18                               Paradoxically, fibrinolytic agents may systemically activate platelets,
19 arin and was significantly attenuated by the fibrinolytic agent streptokinase.
20  an assay for the screening of potential pro-fibrinolytic agents that target PAI-1 inhibition in a hu
21  for simulating the effects of a more potent fibrinolytic agent through direct antithrombin therapy.
22                               An aerosolized fibrinolytic agent, tissue-type plasminogen activator, s
23                                   The use of fibrinolytic agents to prevent new thrombus formation is
24 e studies show the feasibility of delivering fibrinolytic agents to sites of incipient thrombus forma